TY - JOUR
T1 - The effect of dobutamine on myocardial performance and high-energy phosphate metabolism at different stages of heart failure in cardiomyopathic hamsters
T2 - A 31P MRS study
AU - Buser, Peter T.
AU - Camacho, S. Albert
AU - Wu, Shao T.
AU - Higgins, Charles B.
AU - Jasmin, Gaetan
AU - Parmley, William W.
AU - Wikman-Coffelt, Joan
N1 - Funding Information:
From the Departments of Radiologya sity of California Sail Francisco; University of Basel; and Department University of Montreal. Supported by George D. Smith Foundation Health Grant AA07413-01. Dr. Buser is supported by the Swiss National Science Foundation. macho is supported by NationalHeart, Lung, and Blood Institute tional NRSA Grant in Heart and Vascular Diseases, HL07192. Received for publication Dec. 21, 1988; accepted Feb. 2, 1989. Reprint requests: Joan Wikman-Coffelt, PhD, University of California Francisco, Medical Center, 1092 Moffit Hospital, San Francisco, CA
PY - 1989/7
Y1 - 1989/7
N2 - Dobutamine has been shown to exert disparate clinical effects in patients with cardiomyopathy and heart failure. This study evaluated the effects of dobutamine on hemodynamics and energetics in isolated, perfused myopathic hamster hearts at a moderate and advanced stage of heart failure. Biochemical changes were correlated with left ventricular developed pressure, coronary flow, and myocardial oxygen consumption. During dobutamine treatment left ventricular developed pressure increased in the control and moderate heart failure group 28.0 ± 1.0% and 114.2 ± 11.6%, respectively. Myocardial oxygen consumption increased 50.1 ± 9.1% and 45.5 ± 16.0%, respectively. There were no significant changes of left ventricular developed pressure and myocardial oxygen consumption in the advanced heart failure group. Inorganic phosphate (Pi) increased in the control group from 6.8 ± 0.5 to 11.4 ± 1.2 mmol (p < 0.005) and in the advanced heart failure group from 10.4 ± 1.1 to 15.3 ± 1.2 mmol (p < 0.01). Phosphocreatine (PCr) and β-ATP (adenosine triphosphate) decreased in the control group from 12.2 ± 0.4 to 8.7 ± 0.7 mmol (p < 0.001) and 10.4 ± 0.8 to 7.7 ± 0.7 mmol (p < 0.02), respectively. PCr Pi ratio, reflecting mitochondrial function, fell in the control and advanced heart failure group from 1.84 ± 0.14 to 0.84 ± 0.14 (p < 0.02) and 0.81 ± 0.16 to 0.37 ± 0.08 (p < 0.03), respectively. Thus in cardiomyopathic hamsters dobutamine improved mechanical performance and thermodynamic efficiency in moderate stages of heart failure by improving mitochondrial activity, but did not improve mechanical performance in an advanced stage of heart failure. These experiments provide insight into the disparate clinical effects of dobutamine at various stages of heart failure.
AB - Dobutamine has been shown to exert disparate clinical effects in patients with cardiomyopathy and heart failure. This study evaluated the effects of dobutamine on hemodynamics and energetics in isolated, perfused myopathic hamster hearts at a moderate and advanced stage of heart failure. Biochemical changes were correlated with left ventricular developed pressure, coronary flow, and myocardial oxygen consumption. During dobutamine treatment left ventricular developed pressure increased in the control and moderate heart failure group 28.0 ± 1.0% and 114.2 ± 11.6%, respectively. Myocardial oxygen consumption increased 50.1 ± 9.1% and 45.5 ± 16.0%, respectively. There were no significant changes of left ventricular developed pressure and myocardial oxygen consumption in the advanced heart failure group. Inorganic phosphate (Pi) increased in the control group from 6.8 ± 0.5 to 11.4 ± 1.2 mmol (p < 0.005) and in the advanced heart failure group from 10.4 ± 1.1 to 15.3 ± 1.2 mmol (p < 0.01). Phosphocreatine (PCr) and β-ATP (adenosine triphosphate) decreased in the control group from 12.2 ± 0.4 to 8.7 ± 0.7 mmol (p < 0.001) and 10.4 ± 0.8 to 7.7 ± 0.7 mmol (p < 0.02), respectively. PCr Pi ratio, reflecting mitochondrial function, fell in the control and advanced heart failure group from 1.84 ± 0.14 to 0.84 ± 0.14 (p < 0.02) and 0.81 ± 0.16 to 0.37 ± 0.08 (p < 0.03), respectively. Thus in cardiomyopathic hamsters dobutamine improved mechanical performance and thermodynamic efficiency in moderate stages of heart failure by improving mitochondrial activity, but did not improve mechanical performance in an advanced stage of heart failure. These experiments provide insight into the disparate clinical effects of dobutamine at various stages of heart failure.
UR - http://www.scopus.com/inward/record.url?scp=0024316459&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024316459&partnerID=8YFLogxK
U2 - 10.1016/0002-8703(89)90076-8
DO - 10.1016/0002-8703(89)90076-8
M3 - Article
C2 - 2662731
AN - SCOPUS:0024316459
SN - 0002-8703
VL - 118
SP - 86
EP - 91
JO - American heart journal
JF - American heart journal
IS - 1
ER -